Trial Profile
A Study to Evaluate the Efficacy and Safety of Romiplostim in Patients with Primary Immune Thrombocytopenia
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 08 Aug 2021
Price :
$35
*
At a glance
- Drugs Romiplostim (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Adverse reactions; Therapeutic Use
- Acronyms Plateau
- 17 Jun 2021 Results of post hoc analysis assessing the effectiveness and safety of romiplostim in adults with primary ITP, according to ITP phase, in routine clinical practice in Germany presented at the 26th Congress of the European Haematology Association
- 25 Jun 2017 Results (n=59) presented at the 22nd Congress of the European Haematology Association
- 09 Dec 2015 New trial record